What is Tierra Biosciences?
Tierra Biosciences operates as a sophisticated protein discovery engine, fundamentally altering how therapeutics are developed. By integrating AI technology with rigorous biological reality, the company eliminates the traditional guesswork associated with protein synthesis. Their platform provides rapid development and optimization services, catering to the complex needs of the biotechnology and pharmaceutical sectors. As a deep-tech entity, Tierra Biosciences bridges the gap between digital innovation and physical material science, offering high-performance solutions that address critical bottlenecks in drug discovery and therapeutic manufacturing.
How much funding has Tierra Biosciences raised?
Tierra Biosciences has raised a total of $14.9M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$11.4M
Angel/Seed (2020): $3.6M, investors not publicly disclosed
Series A (2024): $11.4M led by In-Q-Tel, Prosus, Material Impact, and Creative Ventures
Key Investors in Tierra Biosciences
In-Q-Tel
A not-for-profit strategic investment firm acting as the U.S. national security community's venture arm, focusing on early-stage commercial technologies including biotech and AI.
Prosus
A global consumer internet group and one of the world's largest technology investors, with a dedicated ventures team focused on health, fintech, and social commerce.
Material Impact
A venture firm focused on building deep tech companies that leverage material science to drive innovation and sustainability.
What's next for Tierra Biosciences?
With the recent influx of capital, Tierra Biosciences is poised to scale its operational capacity and expand its market reach. The strategic focus will likely center on enhancing the throughput of its protein synthesis engine and deepening its integration within the global pharmaceutical supply chain. By maintaining a focus on scalable, deployable technology, the company is well-positioned to address the increasing demand for precision-engineered proteins. Future milestones will likely involve expanding their client base and potentially entering new therapeutic verticals where high-performance protein solutions are essential for clinical success.
See full Tierra Biosciences company page
